WO1998005658A1 - Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1h-imidazole and analogs thereof - Google Patents

Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1h-imidazole and analogs thereof Download PDF

Info

Publication number
WO1998005658A1
WO1998005658A1 PCT/US1997/013805 US9713805W WO9805658A1 WO 1998005658 A1 WO1998005658 A1 WO 1998005658A1 US 9713805 W US9713805 W US 9713805W WO 9805658 A1 WO9805658 A1 WO 9805658A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
reaction
furoyl
furanyl
imidazole
Prior art date
Application number
PCT/US1997/013805
Other languages
French (fr)
Inventor
Taikyun Rho
Michael E. Lankin
David H. Shih
Claire M. Lankin
Original Assignee
Alteon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteon Inc. filed Critical Alteon Inc.
Priority to AU40535/97A priority Critical patent/AU4053597A/en
Publication of WO1998005658A1 publication Critical patent/WO1998005658A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates the synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-lH- imidazole (FFI), and analogs thereof.
  • FFI has been known for a number of years as a fluorescent chromophore formed as a result of the advanced glycosylation process.
  • brown pigments with spectral and fluorescent properties similar to those of late-stage Maillard products have also been observed in vivo in association with several long-lived proteins, such as lens proteins and collagen from aged individuals.
  • An age- related linear increase in pigment was observed in human dura collagen between the ages of 20 to 90 years.
  • the aging of collagen can be mimicked in vitro by the cross-linking induced by glucose: and the capture of other proteins and the formation of adducts by collagen, also noted, is theorized to occur by a cross-linking reaction, and is believed to account for the observed accumulation of albumin and antibodies in kidney basement membrane.
  • FFI FFI was first identified and characterized.
  • Various utilities for FFI have been proposed, among them, therapeutic methods which utilize FFI as an agent to induce macrophage stimulation, and thus accelerate the body's own process for removal of advanced glycosylation endproducts.
  • the present invention relates to a process for the preparation of FFI of the formula I
  • R and R' are as hereinbefore defined;
  • the process of the present invention thus relates to the preparation of FFI of the formula I which comprises the initial reaction of a 2-haloacetyl compound of the formula LI
  • the lower alkyl groups referred to herein contain 1-6 carbon atoms and include methyl, ethyl, propyl, butyl, pentyl, hexyl, and the corresponding branched-chain isomers thereof *
  • the preparation of the 2-acetyl compounds of formula II are described in Dubac et al., Svnth. Commun.. 1991 , 21, p. 1 1 , and Arcorta et al., J. Het. Che .. 1975, 12, page 215.
  • the 1 , 1 -dialkylhydrazines of formula DT are well-known in the an, and are commercially available, for instance, from the Alrich Chemical Co.
  • reaction of the starting material of formula LI with the 1,1-dialkylhydrazine of formula HI is typically conducted in an anhydrous solvent.
  • Typical solvents include ethyl ether, tetrhydrofuran, and the like. Reaction times vary from about 30 minutes to about 2 hours, depending upon the nature of the reactants. Typically, this step is conducted at temperatures ranging from about 0 to about 15 °C.
  • reaction product TV is contacted with methanol at reflux temperatures to afford the desired product of formula I.
  • Typical reaction times for this step vary from 1 to 5 hours, depending upon the particular starting materials being utilized.
  • step (b) results in a rearrangement illustrated by the following reaction scheme, resulting in the preparation of FFI in a facile manner.
  • the FFI of formula I can be further converted to the corresponding alkyl, alkanoic acid, aryl and heteroaryl substituted compounds by reaction with the appropriate halide of the formula V
  • R" is an alkyl, alkanoic acid, aryl or heteroaryl group and X is chloro, bromo or iodo.
  • this reaction is conducted in an anhydrous polar solvent such as dimethylformamide. Typical reaction times vary from 5 to about 12 hours, and reflux temperatures are generally preferred, depending upon the nature of the solvent.
  • the R"-X reactant can contain a blocking group which is then removed in the final steps of the process to afford the desired compound.
  • the alkyl groups can contain from 1 to 10 carbon atoms.
  • the alkanoic acid groups likewise can contain from w to 10 carbon atoms, with hexanoic acid being a preferred substituent.
  • Typical aryl groups include phenyl, and lower alkyl or lower alkoxy substituted phenyl groups.
  • heteroaryl groups aforementioned contain from 4-7 ring members, and contain 1-3 heteroatoms, e.g., oxygen, nitrogen, or sulfur.
  • heterocyclic groups are those such as pyridyl, methylpyridyl, imidazolyl, and pyrrolidinyl.
  • Representative compounds produced by the process of the present invention include: 2-(2-furoyl)-4(5)-(2-furanyl)-lH-imidazole (F ⁇ ); 4-(2 , -furanyl)-2-(2'-furoyl)-lH-imidazole-l -hexanoic acid (FFI-HA); and 4-(2'-furanyl)-2-(2'-furoyl)-lH-imidazole-l -butyric acid (FFI-BA).
  • the title compound can be utilized in the ether solution in further reactions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a practical and facile synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole (FFI) and analogs thereof. The synthesis utilizes a novel hydrazinium salt as an intermediate reaction product which facilitates the isolation of purified product in high yields.

Description

SYNTHESIS OF 2-(2-FUROYL)-4(5)-(2-FURANYL)-lH-IMIDAZOLE
AND ANALOGS THEREOF
B ACKGROI JND OF THE INVENTION
The present invention relates the synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-lH- imidazole (FFI), and analogs thereof. FFI has been known for a number of years as a fluorescent chromophore formed as a result of the advanced glycosylation process.
The reaction between glucose and proteins has been known for some time. Its earliest manifestation was in the appearance of brown pigments during the cooking of food, which was identified by Maillard in 1912, who observed that glucose or other reducing sugars react with amino acids to form adducts that undergo a series of dehydrations and rearrangements to form stable brown pigments. Maillard, C.R. Acad. Sci.. 154. pp. 66-68, (1912). Further studies have suggested that stored and heat treated foods undergo nonenzymatic browning as a result of the reaction between glucose and the polypeptide chain, and that the proteins are resultingly cross-linked and correspondingly exhibit decreased bioavailability.
This reaction between reducing sugars and food proteins was found to have its parallel in vivo. Thus, the nonenzymatic reaction between glucose and the free amino groups on proteins to form a stable, 1 -deoxyketosyl adduct, known as the Amadori product, has been shown to occur with hemoglobin, wherein a rearrangement of the amino terminal of the beta-chain of hemoglobin by reaction with glucose, forms the adduct known as hemoglobin Ale. The reaction has also been found to occur with a variety of other body proteins, such as lens crystallins, collagen and nerve proteins. See, for instance, Bucala et al., "Advanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and Aging," in Advances in Pharmacology. Vol. 23, pp. 1- 34, Academic Press ( 1992).
Moreover, brown pigments with spectral and fluorescent properties similar to those of late-stage Maillard products have also been observed in vivo in association with several long-lived proteins, such as lens proteins and collagen from aged individuals. An age- related linear increase in pigment was observed in human dura collagen between the ages of 20 to 90 years. Interestingly, the aging of collagen can be mimicked in vitro by the cross-linking induced by glucose: and the capture of other proteins and the formation of adducts by collagen, also noted, is theorized to occur by a cross-linking reaction, and is believed to account for the observed accumulation of albumin and antibodies in kidney basement membrane.
In Cerami, U.S. Patent 4,665, 192, FFI was first identified and characterized. Various utilities for FFI have been proposed, among them, therapeutic methods which utilize FFI as an agent to induce macrophage stimulation, and thus accelerate the body's own process for removal of advanced glycosylation endproducts.
Necessary to such therapeutic methods is a ready and facile process for the chemical synthesis of FFI. Heretofore, preparation was by isolation from natural sources, or via the synthetic route proposed by Chang et ai, J. Biol. Chem., 260, pp. 1970-1974 (1985). These methods suffer from poor yields and contaminating by-products which result in the use of difficult purification procedures. The present invention addresses such problems.
SUMMARY OF THE INVENTION
In accordance with the present invention, a facile and productive synthesis of FFI, and analogs thereof, is disclosed.
Thus, the present invention relates to a process for the preparation of FFI of the formula I
Figure imgf000004_0001
which comprises (a) reaction of a 2-haloacetyl compound of the formula II
Figure imgf000004_0002
O (II) wherein X is chloro. bromo or iodo, with 1 , 1-dialkylhydrazine of the formula HI
H2N-NRRr (LTJ)
wherein R and R' are each a lower alkyl group, to afford the compound of formula IV
R'
Figure imgf000005_0001
wherein R and R' are as hereinbefore defined; and
(b) reaction of the compound of formula IV with methanol at reflux temperatures to afford the desired product of formula I.
Accordingly, it is a principal object of the present invention to provide a convenient and facile process for the preparation of 2-(2-furoyl)-4(5)-(2-furanyl)-lH-imidazole (FFI), and analogs thereof, using starting materials which are readily available.
It is a further object of the present invention to provide a process as aforesaid which minimizes by-product formation and thus affords the desired product in a relatively pure state, thus obviating the necessity for additional complicated purification procedures.
Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing description.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In accordance with the present invention, disclosed is a process for the preparation of compounds of the following formula I
Figure imgf000006_0001
The process of the present invention thus relates to the preparation of FFI of the formula I which comprises the initial reaction of a 2-haloacetyl compound of the formula LI
Figure imgf000006_0002
O
wherein X is chloro. bromo or iodo, with 1,1-dialkylhydrazine of the formula ILT
Figure imgf000006_0003
wherein R and R' are each a lower alkyl group, to afford the compound of formula IV
R'
Figure imgf000006_0004
wherein R and R' are as hereinbefore defined.
The lower alkyl groups referred to herein contain 1-6 carbon atoms and include methyl, ethyl, propyl, butyl, pentyl, hexyl, and the corresponding branched-chain isomers thereof* The preparation of the 2-acetyl compounds of formula II are described in Dubac et al., Svnth. Commun.. 1991 , 21, p. 1 1 , and Arcorta et al., J. Het. Che .. 1975, 12, page 215. The 1 , 1 -dialkylhydrazines of formula DT are well-known in the an, and are commercially available, for instance, from the Alrich Chemical Co.
The reaction of the starting material of formula LI with the 1,1-dialkylhydrazine of formula HI is typically conducted in an anhydrous solvent. Typical solvents include ethyl ether, tetrhydrofuran, and the like. Reaction times vary from about 30 minutes to about 2 hours, depending upon the nature of the reactants. Typically, this step is conducted at temperatures ranging from about 0 to about 15 °C.
In subsequent reaction step (b), the reaction product TV is contacted with methanol at reflux temperatures to afford the desired product of formula I. Typical reaction times for this step vary from 1 to 5 hours, depending upon the particular starting materials being utilized.
While not wishing to be bound by any mechanistic theory, it is believed that the subsequent step (b) results in a rearrangement illustrated by the following reaction scheme, resulting in the preparation of FFI in a facile manner.
In the following Scheme I, the reaction is illustrated using X = Br and R and R' = methyl
Scheme I
Figure imgf000008_0001
-Me,NH HBr
Figure imgf000008_0002
I
Figure imgf000008_0003
The FFI of formula I can be further converted to the corresponding alkyl, alkanoic acid, aryl and heteroaryl substituted compounds by reaction with the appropriate halide of the formula V
R"-X (V)
wherein R" is an alkyl, alkanoic acid, aryl or heteroaryl group and X is chloro, bromo or iodo. Typically, this reaction is conducted in an anhydrous polar solvent such as dimethylformamide. Typical reaction times vary from 5 to about 12 hours, and reflux temperatures are generally preferred, depending upon the nature of the solvent. Where necessary, the R"-X reactant can contain a blocking group which is then removed in the final steps of the process to afford the desired compound.
The alkyl groups can contain from 1 to 10 carbon atoms. The alkanoic acid groups likewise can contain from w to 10 carbon atoms, with hexanoic acid being a preferred substituent.
Typical aryl groups include phenyl, and lower alkyl or lower alkoxy substituted phenyl groups.
The heteroaryl groups aforementioned contain from 4-7 ring members, and contain 1-3 heteroatoms, e.g., oxygen, nitrogen, or sulfur. Representatives of such heterocyclic groups are those such as pyridyl, methylpyridyl, imidazolyl, and pyrrolidinyl.
Representative compounds produced by the process of the present invention include: 2-(2-furoyl)-4(5)-(2-furanyl)-lH-imidazole (Fπ); 4-(2,-furanyl)-2-(2'-furoyl)-lH-imidazole-l -hexanoic acid (FFI-HA); and 4-(2'-furanyl)-2-(2'-furoyl)-lH-imidazole-l -butyric acid (FFI-BA).
The present invention will be better understood from a consideration of the following examples, which describe the preparation of compounds according to processes illustrative of the present invention. It will be apparent to those skilled in the art that many modifications, both of materials and methods, may be practiced without departing from the purpose and intent of this disclosure. EXAMPLES
Preparation of Starting Materials EXAMPLE A 2-Bromoacetylfuran
To a 5 liter round bottomed flask is added 2-acetylfuran (440 grams, 4 moles) and 2.4 liters of ethyl ether at 5 C in an ice bath. To this solution is added, dropwise over a period of two hours, with vigorous stirring, 230 mL bromine (713 grams, 4.46 moles). After the bromine addition is complete, the reaction mixture is stirred for an additional two hours, and then quenched with the addition of 300 mL of water. The mixture is then allowed to separate overnight, and the ether layer is washed with water (3 x 300 mL), dried over magnesium sulfate, and filtered. Removal of the solvent affords the title product having Η-NMR (CDC13) delta 7.53 (t, U, J=0.72 Hz), 7.21 (d, 1H, J=3.68 Hz), 6.46 (dd, 1H, J=3.66 Hz and 1.48 Hz), 4.20 (s, 2H). "C (CDCI3 189.22, 150.12, 147.61 , 1 19.42, 1 12.93, 30.46 ppm.
Alternately, the title compound can be utilized in the ether solution in further reactions.
Preparation of Compounds of Formula I
EXAMPLE 1 2-f 2-Furoyl)-4f 5 W2-furanyl)- 1 H-imidazole A. In a 5 liter round bottomed flask equipped with a mechanical stirrer adn an addition funnel, is placed 2-bromoacetylfuran (560 g, 2.95 mol, assumed 75% from acetylfuran in ether (3,2L)). The solution is cooled to 5 °C. in an ice bath and 1,1 -dimethyl hydrazine (178 g, 2.96 mole) is added dropwise over a period of one and one-half hours. As the hydrazine is added, a yellow solid begins to precipitate out and the reaction mixture becomes very thick. After the addition is completed, the mixture is stirred an additional hour and allowed to stand for an additional two hours. The off- white solid is collected and dried under vacuum for three days to afford 1, 1 -dimethyl- 1- (2'-furoyl)hydrazinium bromide (720 g, 72% yield), having a melting point of 134-135
°C. 1H-NMR (DMSO-d6) δ 8.18 (1H, d. J=0.72 Hz), 7.77 (1H, d, J=3.64 Hz), 6.85
(lH.dd, J=3.64 Hz and 1.45 Hz). "C (DMSO-d6) 179.16, 150.65, 150.31, 122.19, 1 13,84, 688.81 , 56.94 ppm. To a 5 liter round bottomed flask is added the hydrazinium bromide produced in step (a) detailed in the foregoing paragraph (300 g, 1.2 mole) and methanol (2.4 L). The solids slowly dissolve as the mixture is heated to reflux temperatures. The reaction mixture is then refluxed for three hours, whereupon most of the methanol is removed in vacuo. The resultant oil is poured onto ice water ( 1.5 L) and the aqueous mixture is stirred overnight. The brown solid is collected and recrystallized from methanol/ether to afford the 2-(2-furoyl)-4(5)-(2-furanyl)-lH-imidazole title product as yellow crystals (85 g, 62% yield), having identical properties to those reported in the literature.
EXAMPLE 2
A. To a 100 mL round bottom flask was added FFI (3.0 g, 13.2 mmoQD and dry DMF (45 mL) under nitrogen. Sodium hydride (475 mg, 19.8 mmol) was added to the reaction mixture. This mixture was stirred at 90°C and ethyl 6-bromohexanoate (3.24 g, 14.5 mmol) was added. The reaction mixture was stirred at 90°C for 10 hours under nitrogen. After removing the solvent by high vacuum distillation, the dark reddish oil was recrystallized from tert-butyl methyl ether to give ethyl 4-(2'-furanyl)-2-(2'- furoyl)-lH-imidazole-l-hexanoate, as a yellow crystal 2.0 g (41%); mp 65-66°C. 1H-
NMR (CDC13) δ 8.18 ( IH, d, J=3.68 Hz), 7.71 ( IH, m), 7.41 (IH, m), 7.34 (IH, s), 6.72 ( IH, d, J=3.28 Hz), 6.61 ( IH, dd, J=3.5 Hz and 1.65 Hz), 6.47 (IH, dd, J=3.28 Hz and 1.84 Hz), 4.47 (2H, t, J=7.32 Hz), 4.1 1(2H, q, J=7.32 Hz), 2.29 (2H, t, J=7.52 Hz), 1.90 (2H, m), 1.68 (2H, t, J=7.32 Hz), 1.40(2H, m), 1.23 (3H, t, J=7.34 Hz). 13C-NMR (CDC13) 173.5, 170.2, 151.3, 149.2, 147.6, 141.6,
141.1, 134.5, 123.7, 121.6, 112.6, 1 1 1.4, 105.4, 60.3, 48.9, 34.1, 30.9, 26.1, 24.5, 14.3 ppm. Anal. Calcd for C20H22N2O5: C, 68.45; H, 5.99; N, 7.54. Found C, 64.56; H, 5.95; N, 7.40.
B .
To a 250 mL round bottomed flask was placed the ethyl ester prepared as detailed in the above paragraph A (1.0 g, 2.7 mmol), methanol (20 mL) and barium hydroxide monohydrate (0.56 g, 3 mmol). The mixture was stirred for 40 hours at room temperature. Solids were filtered off, and the filtrate was concentrated in vacuo to give a yellow oil. To the oil was added water (20 mL), and PH was adjusted to 4 by adding 6N HCl in an ice bath. The aqueous layer was extracted with methylene chloride (2 x 20 mL). The organic layers were combined and evaporated in vacuo to give a yellow solid. The solid was recrystallized from chlorofor /hexane to give 4-(2'- furanyl)-2-(2'-furoyl)-lH-imidazole-l -hexanoic acid as a off-white crystal (0.82 g, 84%); mp 105-106°C. IH-NMR (CDCl3) δ 8.18 ( IH, d, J=3.68), 7.71 (IH, m), 7.41
( IH, m), 7.35 ( IH, s), 6.72 (IH, d, J=3.28 Hz), 6.60 ( IH, dd, J=3.5 Hz and 1.65 Hz), 6.47 ( IH, dd, J=3.28 Hz and 1.84 Hz), 4.47 (2H, t, J=7.32 Hz), 2.36 (2H, t, J=7.32 Hz), 1.89 (2H, m), 1.69 (2H, m). πC-NMR (CDCI3) 179.2, 170.3, 151.3, 149.2, 147.4, 141.6, 14.2, 134.5, 123.8, 121.6, 1 12.6, 1 1 1.5, 105.4, 48.9, 33.8, 30.9, 26.0, 24.1 ppm.
Example 3
A. To a 250 mL round bottomed flask was placed FFI (5.0 g, 22 mmol) and dry DMF ( 100 mL) under dry N2 atmosphere. To the mixture was added sodium hydride
(60%. l.Og, 25 mmol) and stirred for 15 minutes. 1 ,6-Dibromohexane (1 1.0 g, 45 mmol) was added all at once. The mixture was heated to 85°C and stirred for 14 hours. The solvent was removed by high vacuum distillation. To the oily residue was added water (100 mL) and extracted with chloroform (80 mL x 3). The organic layer was washed with water (50 mL) and dried over anhydrous MgSO4. The unreacted dibromohexane was removed by flash chromatography over TLC grade silica gel (100 g) with chloroform/hexane (1: 1). Upon evaporation of the solvent, 5.5 g of 4-(2'- Furanyl)-2-(2'-furoyl)- lH-l-(6'-bromohexyI)imidazole, as a yellow oil (65%), was obtained. IH-NMR (CDCI3) δ 8.17 (IH, d, J=3.28 Hz), 6.59 (IH, dd, J=3.5 Hz and 1.65 Hz), 6.46 (IH, dd, J=3.27 Hz and 1.85 Hz), 4.45 (2H, t,J=7.3 Hz), 3.36 (2H, t, J=7.3 Hz), 1.86 (4H, m), 1.49-1.35 (4H, m). ^C-NMR (CDCI3) 170.3, 151.4, 149.2, 147.7, 141.6, 141.2, 134.5, 123.8, 121.6, 112.6, 1 1 1.5, 105.4, 49.0, 33.7, 32.6, 31.1, 27.7, 25.8 ppm.
B. Bromohexyl-FFI (5.0g, 12.8 mmol) and sodium azide (0.9 g, 13.8 mmol) were dissolved in the mixture of methanol (50 mL) and water (100 mL). The mixture as refluxed for 12 hours and extracted with chloroform (2xl00mL). The organic layer was washed with water (50 ML) and dried over anhydrous MgSO . After removing the solvent, 3.2 g of 4-(2'-furanyl)-2-(2'-furoyl)-lH-l-(6'-azidohexyl)imidazole, as a yellow oil, was obtained. IH-NMR (CDC13) δ 8.17 (IH, d, J=3.67 Hz), 7.70 ( IH, t,
J=0.74 Hz), 7.40 ( I H. m), 7.33 ( lH,s), 6.71 ( IH, d, J=3.28 Hz), 6.60 (IH, dd, J=3.5 Hz and 1.65 Hz). 6.46 ( IH, dd, J=3.27 Hz and 1.85 Hz), 4.45 (2h, t, j=7.3 Hz), 3.32 (2H, t, J=7.3 Hz), 3.32 (2H, t, J=7.3 Hz), 1.86 (2H, m) 1.57 (2H, m), 1.39 (4H, m). 13C-NMR (CDC13) 170.3, 151.3, 149.2, 147.7, 141.6,, 141.2, 134.5, 123.8, 121.6, 1 12.6, 1 1 1.5, 105.4, 51.3, 49.0, 31.1 , 28.7, 26.3, 26.1 ppm.
C . To a 250mL round bottom flask was added the azide (0.5 g, 1.4 mmol), tetrahydrofuran (THF) (150 mL), water (50 mL) and triphenyl phosphine (0.37 g, 1.4 mmol). The mixture was stirred for 14 hours and solvent was removed in vacuo. To the residue was added 20 mL of water and extracted with chloroform (2X20 mL). After flash chromatography over tic grade silica gel (50 mL), 0.32 g of 4-(2'-furanyl)- 2-(2'-furoyl)-lH- l-(6'-aminohexyl)imidazole, as a pure oil, was obtained. 'H-NMR
(CDCI3) δ 8.17 ( IH. d. J=3.67 Hz), 7.71 ( IH, t, J=0.74 Hz), 7.41 (IH.m), 7.33 ( l H,s), 6.71 ( IH, d. J=3.28 Hz), 6.60 ( IH, dd, J=3.5 Hz and 1.65 Hz), 6.46 (IH, dd, J=3.27 Hz and 1.85 Hz), 4.34 (2H, t, J=7.3 Hz), 3.48 (2H, br s),), 2.68 (2H,m), 1.74 (2H,br s), 1.17 (4H, br s).
This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

Claims

WHA IS qAJMED IS:
A process for the preparation of FFI of the formula I
Figure imgf000014_0001
H O which comprises (a) reaction of a 2-haloacetyl compound of the formula LI
Figure imgf000014_0002
O with 1 , 1-dimethylhydrazine of the formula m
H2N-NRR' (LLI)
wherein R and R' are lower alkyl groups, to afford the compound of formula LV
Figure imgf000014_0003
wherein R and R' are as hereinbefore defined; (b) reaction of the compound of formula IV with methanol at reflux temperatures to afford the desired product of formula I.
2. The process of Claim 1 wherein R and R are both methyl groups.
3. The process of Claim 1 wherein X is bromo.
4. The process of Claim 1 which further includes reaction of the 2-(2-furoyl)-4(5)-(2- furanyl)-lH-imidazole with R"-X to produce the substituted-FFI compound.
PCT/US1997/013805 1996-08-07 1997-08-07 Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1h-imidazole and analogs thereof WO1998005658A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40535/97A AU4053597A (en) 1996-08-07 1997-08-07 Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1h-imidazole and analogs thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69103596A 1996-08-07 1996-08-07
US08/691,035 1996-08-07

Publications (1)

Publication Number Publication Date
WO1998005658A1 true WO1998005658A1 (en) 1998-02-12

Family

ID=24774912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013805 WO1998005658A1 (en) 1996-08-07 1997-08-07 Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1h-imidazole and analogs thereof

Country Status (2)

Country Link
AU (1) AU4053597A (en)
WO (1) WO1998005658A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004169A1 (en) * 1984-03-19 1985-09-26 The Rockefeller University Method and agents for measuring protein aging
US4761368A (en) * 1986-07-15 1988-08-02 The Rockefeller University Method and agents for measuring protein aging

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004169A1 (en) * 1984-03-19 1985-09-26 The Rockefeller University Method and agents for measuring protein aging
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4761368A (en) * 1986-07-15 1988-08-02 The Rockefeller University Method and agents for measuring protein aging

Also Published As

Publication number Publication date
AU4053597A (en) 1998-02-25

Similar Documents

Publication Publication Date Title
KR20160131129A (en) Process for the synthesis of halogenated cyclic compounds
JPH0730031B2 (en) Process for producing 2-pyrazolin-5-ones
EP0205879B1 (en) Process for the preparation of herbicidal 2-(4,4-disubstituted 5-oxo-2-imidazolin-2-yl)benzoic, nicotinic and quinoline-3-carboxylic acids, esters and salts
JP3670314B2 (en) Process for producing 1-substituted-5 (4H) -tetrazolinones
KR960001913B1 (en) Process for the preparation of 3-cyano-4-aryl-pyrroles
US5552557A (en) Process for preparing 2-cyanoimidazole compounds by reaction of an amino ketone compound
US5856511A (en) Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole and analogs thereof
WO1998005658A1 (en) Synthesis of 2-(2-furoyl)-4(5)-(2-furanyl)-1h-imidazole and analogs thereof
JP2524491B2 (en) Novel aminocarboxylic acid ester and process for producing the same
JP2007523098A (en) Catalytic asymmetric synthesis of optically active α-halo-carbonyl compounds
JPH09194464A (en) Production of 2-substituted 5-chloroimdazole-4-carbaldehyde
JP4143740B2 (en) Process for producing substituted pyrimidine derivatives
JP2578797B2 (en) Method for producing N- (sulfonylmethyl) formamides
JPH0641135A (en) Imidazopteridine derivative and its production
RU2116299C1 (en) Method of synthesis of 2-substituted 5-chloroimidazole-4-carbaldehydes and 2-substituted 3,5-dihydroimidazoline-4-one
CN112135820B (en) Novel process for preparing diaminopyrimidine derivatives or acid addition salts thereof
JP3159860B2 (en) Method for synthesizing 4,5-diformylimidazole compound and novel imidazole compound
JP3252484B2 (en) Method for producing 4,5-dihydro [1,2,4] triazolo [4,3-a] quinoxaline derivative
JPH07188180A (en) Production of 2-substituted-5-chloroimidazole-4-carbaldehyde
KR100539725B1 (en) New alkylation of pyrrole compound
JP4004082B2 (en) Method for producing cyclic nitroguanidine derivatives
RU2042671C1 (en) Diketoneimine derivative as an intermediate product for synthesis of ranitidine and method of its synthesis
KR100566318B1 (en) A process for preparing carbazolone derivatives
EP0322691A1 (en) Process for producing 1-acyl-2-pyrazoline derivatives
US4294760A (en) Preparation of 5-(arylcyanohydroxymethyl)-1-loweralkylpyrrole-2-acetic acid derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998508183

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA